7. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)
Price: $18.26 per share
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has strengthened its position as a clinical-stage biopharmaceutical stock to watch following the pricing of an upsized public offering that is expected to generate approximately $175 million in gross proceeds, a move that significantly enhances its balance sheet and extends its operational runway. By issuing 7,900,677 shares at $22.15 per share, with an additional 30-day option for underwriters to purchase more shares, Corvus demonstrated strong institutional demand at a premium biotech financing level, signaling investor confidence in its long-term immunotherapy strategy. For a biotech stock advancing multiple clinical trials, access to capital is often the decisive factor between stagnation and accelerated development, and this financing meaningfully de-risks near-term execution.
The company intends to deploy the proceeds toward working capital and research and development, including its Phase 3 clinical trial for relapsed or refractory peripheral T-cell lymphoma and Phase 2 programs in atopic dermatitis, hidradenitis suppurativa, and asthma. At the center of the investment thesis is soquelitinib, an oral small molecule ITK inhibitor that represents a differentiated immunotherapy approach targeting immune diseases and cancer. As precision immunology continues to gain traction across the biotech sector, Corvus’ focus on selective ITK inhibition positions it within a high-value niche that could unlock both oncology and inflammatory disease markets if clinical data remain supportive.
Importantly, the offering was led by major investment banks including Jefferies and Goldman Sachs, with Mizuho and Ladenburg Thalmann participating, underscoring institutional validation of the company’s development pipeline. With a strengthened capital base, advancing late-stage oncology programs, and multiple mid-stage inflammatory indications, CRVS stock now trades with improved financial visibility and reduced dilution risk in the near term. For investors seeking exposure to high-upside biotech stocks with active Phase 3 catalysts and a clearly funded development strategy, Corvus Pharmaceuticals presents a compelling growth narrative rooted in innovative immunotherapy, disciplined capital markets execution, and expanding clinical momentum.
Click next to see the following stock...
